Alemtuzumab and multiple sclerosis: Therapeutic application

Expert Opinion on Biological Therapy

Volumn 10, Issue 3, 2010, Pages 421-429

  Minagar, Alireza ^a   Alexander, J Steven ^b   Sahraian, Mohammad Ali ^c,e   Zivadinov, Robert ^d  

^a Louisiana State University School of Medicine Shreveport   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e JACOBS NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Alemtuzumab; Campath; CD52; Monoclonal antibody; MRI; Multiple sclerosis

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; DIPHENHYDRAMINE; METHYLPREDNISOLONE; PARACETAMOL;

AUTOIMMUNE SKIN DISEASE; B LYMPHOCYTE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; FEVER; HEADACHE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE SYSTEM; LYMPHOCYTE SUBPOPULATION; MONOCYTE; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; RASH; REVIEW; RIGOR; T LYMPHOCYTE; THYMOCYTE; THYROID DISEASE; VOMITING;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CLINICAL TRIALS AS TOPIC; HUMANS; MULTIPLE SCLEROSIS;

EID: 76949097511     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712591003586806     Document Type: Review

References (62)

1. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006;354:942-955
2. Bar-Or A. Immunology of multiple sclerosis. Neurol Clin 2005;23(1):149-175
3. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285
4. Minagar A, Alexander JS. Blood-brain barrier disruption in multiple sclerosis. Mult Scler 2003;9(6):540-549
5. Minagar A, Alexander JS, Schwendimann RN, et al. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. Arch Neurol 2008;65(2):199-204
6. Frohman EM, Eagar T, Monson N, et al. Immunologic mechanisms of multiple sclerosis. Neuroimaging Clin N Am 2008;18:577-588
7. Severson C, Hafler DA. T-cells in multiple sclerosis. Results Probl Cell Differ 2010: published online 7 July 2009, doi: 10.1007/400-2009-12
8. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123-1132
9. Balashov KE, Smith DR, Khoury SJ, et al. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci USA 1997;94:599-603
10. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. 1986. J Immunol 2005;175:5-14
11. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991;325:467-472
12. Hohlfeld R, Wekerle H. Immunological update on multiple sclerosis. Curr Opin Neurol 2001;14:299-304
13. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007;8:913-919
14. Langrish CL, Chen Y, BlumenscheinWM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201:233-240
15. Durelli L, Conti L, Clerico M, et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 2009;65:499-509
16. Weaver CT, Hatton RD, Mangan PR, et al. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25:821-852
17. Matusevicius D, Kivisäkk P, He B, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999;5:101-104
18. Lock C, Hermans G, Pedotti R, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002;8:500-508
19. Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008;172:146-155
20. Bowman EP, Chackerian AA, Cua DJ. Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy. Curr Opin Infect Dis 2006;19:245-252
21. Qin S, Cobbold SP, Pope H, et al. "Infectious" transplantation tolerance. Science 1993;259:974-977
22. Qin Y, Duquette P, Zhang Y, et al. Clonal expansion and somatic hypermutation of VH genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest 1998;102:1045-1050
23. Serafini B, Rosicarelli B, Magliozzi R, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004;14:164-174
24. Hale C, Bartholomew M, Taylor V, et al. Recognition of CD52 allelic gene products by CAMPATH-1H antibodies. Immunology 1996;88:183-190
25. Hale G, Xia MQ, Tighe HP, et al. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990;35:118-127
26. Elsner J, Höchstetter R, Spiekermann K, et al. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 1996;88:4684-4693
27. Rodig SJ, Abramson JS, Pinkus GS, et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006;12:7174-7179
28. Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 2001;3:137-143
29. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993;82:807-812
30. Yamaguchi R, Yamagata K, Hasuwa H, et al. Cd52, known as a major maturation-associated sperm membrane antigen secreted from the epididymis, is not required for fertilization in the mouse. Genes Cells 2008;13:851-861
31. Klabusay M, Sukova V, Coupek P, et al. Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases. Cytometry B Clin Cytom 2007;72:363-370
32. Hale G. CD52 (CAMPATH1). J Biol Regul Homeost Agents 2001;15:386-391
33. Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009;128(2):260-270
34. Rowan W, Tite J, Topley P, Brett SJ. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B-and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Int Immunol 1995;7:69-77
35. Masuyama J, Yoshio T, Suzuki K, et al. Characterization of the 4C8 antigen involved in transendothelial migration of CD26hi T cells after tight adhesion to human umbilical vein endothelial cell monolayers. J Exp Med 1999;189(6):979-990
36. Watanabe T, Masuyama J, Sohma Y, et al. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin Immunol 2006;120:247-259
37. Xia MQ, Tone M, Packman L, et al. Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol 1991;21:1677-1684
38. Xia MQ, Hale G, Lifely MR, et al. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993;293(Pt 3):633-640
39. Nückel H, Frey UH, Röth A, et al. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibodydependent cellular cytotoxicity. Eur J Pharmacol 2005;514:217-224
40. Stanglmaier M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol 2004;83:634-645
41. Thompson SA, Jones JL, Cox AL, et al. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol 2009: published online 10 September 2009, doi: 10.1007/s10875-009-9327-3
42. Barth RN, Janus CA, Lillesand CA, et al. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int 2006;19:885-892
43. Tan HP, Kaczorowski DJ, Basu A, et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006;6:2409-2417
44. Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with thymoglobulin or Campath. J Am Coll Surg 2005;200:505-515
45. Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int 2006;19(9):705-714
46. Benjamin RJ, Waldmann H. Induction of tolerance by monoclonal antibody therapy. Nature 1986;320:449-451
47. Moreau T, Thorpe J, Miller D, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994;344:298-301
48. Ashton DS, Beddell CR, Cooper DJ, et al. Mass spectrometry of the humanized monoclonal antibody CAMPATH 1H. Anal Chem 1995;67:835-842
49. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46:296-304
50. Paolillo A, Coles AJ, Molyneux PD, et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 1999;53:751-757
51. Cox AL, Thompson SA, Jones JL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005;35:3332-3342
52. Hirst CL, Pace A, Pickersgill TP, et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol 2008;255:231-238
53. Coles AJ, Compston DA, Selmaj KW, et al.; CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-1801
54. Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996;119(Pt 6):2009-2019
55. Clatworthy MR, Wallin EF, Jayne DR. Anti-glomerular basement membrane disease after alemtuzumab. N Engl J Med 2008;359:768-769
56. Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996;119(Pt 1):225-237
57. Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009;119:2052-2061
58. Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/ refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis 2008;67:1322-1327
59. Sullivan H. The CAMMS223 Study Group. ITP following treatment of multiple sclerosis patients with alemtuzumab in CAMMS223; case reports and risk management plan implementation [AAN abstract S32.004]. Neurology 2007;68(Suppl 1):A206
60. Coles AJ, on behalf of CAMMS223 study group. Alemtuzumab treatment benefit is durable: primary efficacy outcomes of CAMMS223 at 4 Years, ECTRIMS 2009; P890. Mult Scler 2009;15:S277
61. Pace AA, Zajicek JP. Melanoma following treatment with alemtuzumab for multiple sclerosis. Eur J Neurol 2009;16:e70-1
62. Kremenchutzky M, Rice GP, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006;129(Pt 3):584-594